Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQ tree SLIT-tablet for birch pollen-induced allergic rhinoconjunctivitis
2015-004821-15Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Mar 2016
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic conjunctivitis (AC), allergic rhinoconjunctivitis (ARC) and 1 more comparing SQ tree SLIT-tablet with Placebo (2 arms). Primary endpoint: Combined rhinoconjunctivitis symptom and medication score. Started Mar 2016; status: completed.
02
Drugs
birch pollen allergen extract
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)allergic rhinoconjunctivitis (ARC)birch pollen allergy
Beyond the preview
Go deeper on 2015-004821-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004821-15.